Our business strategy is two-fold:
- Develop innovative drugs from our proprietary cadherin-based biotechnology platform, which target certain tumor cells and the tumor blood vessels, then partner for the later-stage development and commercialization of these drugs.
- In-license later-stage oncology products that we can systematically advance through clinical development towards commercialization, either in partnership or by ourselves.
We recognize that each step we take in the value chain towards commercialization makes our products more attractive to both potential partners and to the investment community. We seek to make continuous and systematic progress in our product development programs, thereby strengthening our ability to seek and complete the most attractive partnership, collaboration and business development deals.
